作者
Chao Bai,Wenwen Yang,Pengfei Xu,Tuerdebieke Jiakesileke,Xiaoyun Ni,S Y Li,Tao Liu
摘要
Abstract Background To investigate the molecular mechanism by which deoxyshikonin (DS) modulates hsa-HLA-DRB1 to ameliorate high glucose (HG)-induced dysfunction in human umbilical vein endothelial cells (HUVECs) and to evaluate its regulatory effect on wound healing in a diabetic mouse model, thereby providing an experimental basis and a targeted therapeutic strategy for diabetic foot ulcers (DFU). Methods An in vitro model was established using HUVECs subjected to HG and hsa-HLA-DRB1 overexpression with or without DS intervention. Differentially expressed genes (DEGs) were identified via RNA sequencing (RNA-seq). Cell proliferation, migration, tube formation, and apoptosis were assessed using CCK-8, wound healing, tube formation assays, and flow cytometry, respectively. Key pathway molecules and inflammatory cytokines were quantified using real-time quantitative PCR (RT-qPCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA). Dual-luciferase reporter assays were performed to validate the targeting relationships between hsa-HLA-DRB1 and miRNA-12118, and between miRNA-12118 and FLT-1. An in vivo model was established using C57BL/6 diabetic mice with dorsal skin wounds. Wounds were locally injected with lentivirus overexpressing hsa-HLA-DRB1. Mice were randomized into five groups: normal control, diabetes mellitus (DM), DM + DS, DM + hsa-HLA-DRB1 lentivirus (OE-hsa-HLA-DRB1), and DM + OE-hsa-HLA-DRB1 + DS. Wound healing rates were calculated, and molecular markers were analyzed. Results RNA-seq analysis identified 2,415 DEGs across the four cell groups, with significant enrichment in pathways related to immune inflammation, signal transduction, and angiogenesis. Dual-luciferase assays confirmed direct binding between hsa-HLA-DRB1 and miRNA-12118, and between miRNA-12118 and FLT-1. Overexpression of hsa-HLA-DRB1 under HG conditions significantly inhibited HUVEC migration, proliferation, and tube formation (P < 0.05), enhanced the inflammatory response (P < 0.05), but had no significant effect on apoptosis. Intervention with 3 µmol/L DS reversed these cellular phenotypes, downregulated the expression of molecules such as CXCL12 (P < 0.05), and decreased the concentrations of IL-6 and TNF-α (P < 0.001). In vivo, the wound healing rate in the DM + OE-hsa-HLA-DRB1 group was significantly lower than that in the DM group (P < 0.01), with high hsa-HLA-DRB1 expression and a markedly enhanced inflammatory response in wound tissue. DS treatment significantly increased the wound healing rate in both the DM and DM + OE-hsa-HLA-DRB1 groups. In vivo, the normal control group showed a 14-day wound healing rate of 95.2 ± 2.35%. The DM group exhibited delayed healing (87.4 ± 3.86%, P < 0.001 vs. control). The DM + OE-hsa-HLA-DRB1 group had significantly impaired healing (85.4 ± 4.12%, P < 0.01 vs. DM). DS treatment markedly improved healing: the DM + DS group reached 92.5 ± 3.26% (P < 0.001 vs. DM), and the DM + OE-hsa-HLA-DRB1 + DS group achieved 93.3 ± 3.58% (P < 0.001 vs. DM + OE-hsa-HLA-DRB1). RT-qPCR and Western blot analyses confirmed that DS inhibited the activation of the PI3K/Akt and TNF inflammatory pathways, alleviated oxidative stress injury, and promoted granulation tissue formation, angiogenesis, and re-epithelialization. Conclusions DS targets the hsa-HLA-DRB1, effectively ameliorating HG-induced HUVEC dysfunction in vitro and reversing hsa-HLA-DRB1 overexpression-mediated delayed wound healing in diabetic mice in vivo. These findings identify DS as a promising therapeutic candidate and hsa-HLA-DRB1 as a potential target for DFU treatment.